Rita Nanda to Neoplasm Metastasis
This is a "connection" page, showing publications Rita Nanda has written about Neoplasm Metastasis.
Connection Strength
0.847
-
Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer. JAMA Netw Open. 2026 Apr 01; 9(4):e268908.
Score: 0.179
-
Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer. Sci Adv. 2024 10 25; 10(43):eadp2622.
Score: 0.162
-
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024 Nov; 208(1):203-214.
Score: 0.158
-
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. J Clin Oncol. 2026 Mar 10; 44(8):653-661.
Score: 0.044
-
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 12 20; 38(36):4274-4282.
Score: 0.031
-
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 05 01; 26(9):2111-2123.
Score: 0.029
-
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82.
Score: 0.027
-
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Res Treat. 2018 Oct; 171(3):637-648.
Score: 0.026
-
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 03 20; 36(9):884-890.
Score: 0.025
-
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med. 2017 10 11; 15(1):205.
Score: 0.025
-
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
Score: 0.024
-
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. J Clin Oncol. 2017 Mar; 35(7):751-758.
Score: 0.023
-
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
Score: 0.021
-
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21(12):2771-9.
Score: 0.021
-
The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013 Jul; 43(1):5-12.
Score: 0.018
-
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
Score: 0.018
-
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
Score: 0.017